Arca
Skip to content
Tools
Tools

Candidiasis

Drug research and approvals for candidiasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 25 studies of candidiasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 2 approved and 5 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 25
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 2
  • EU medicines: 6

Recruiting Now

Newest start dates first, of 25 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

14 approved, 2 in phase 3, 2 in phase 2; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Fluconazole, Anidulafungin, Amphotericin b, Caspofungin, Micafungin, Voriconazole, Clotrimazole, Itraconazole, Nystatin, Flucytosine, Griseofulvin, Posaconazole, Ciclopirox, Rezafungin

Metronidazole
Phase 3 DNA inhibitor
Tinidazole
Phase 3 DNA disrupting agent
Prednicarbate
Phase 2 Glucocorticoid receptor agonist
Octenidine
Phase 2 Antiseptic

How Its Trials Ended

288 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 65 whose ending is known, 52% met their primary endpoint, 8% missed it and 40% stopped early.

  • Completed, result not reported16156%
  • Met its primary endpoint3412%
  • Ongoing3412%
  • Status unknown2810%
  • Stopped: other or unclear145%
  • Stopped: enrollment or feasibility124%
  • Missed its primary endpoint52%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Oct 30, 2023Phase 1 single centre, open-labeled clinical trial to evaluate the safety and tolerability of topical nitric oxide releasing mouthwash (norm) for the…Nitric oxideSanotize Research & Development CorpClosed
Feb 7, 2023A phase 3, multicenter, prospective, randomized, double-blind study of two treatment regimens for candidemia and/or invasive candidiasis: intravenous…Ibrexafungerp (SCY-078)ScynexisClosed
Sep 12, 2018A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vt-1161 oral capsules in the treatment of subjects with…Oteseconazole (VT-1161)/ fluconazoleMycovia PharmaceuticalsClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Jul 16, 2026RezzayoIn adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and…Mundipharma GmbHApproved
Mar 22, 2023RezzayoIn patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasisMundipharma GmbHApproved
Mar 15, 2026Triterpenoid antifungalTreatment of invasive candidiasisSCYNEXIS, Inc.Designated
Nov 1, 2021MiltefosineTreatment invasive candidiasisProfounda, lnc.Designated
Oct 19, 2016FosmanogepixTreatment of invasive candidiasisBasilea Pharmaceutica Ltd, AllschwilDesignated
Oct 20, 2014Isavuconazonium sulfateTreatment of invasive candidiasis/candidemiaAstellas Pharma Global Development, Inc.Designated
Jun 27, 1996Amphotericin B lipid complexTreatment of invasive candidiasis.The Liposome Company, Inc.Designated

Medicines Authorised in the EU

Newest first
Dec 22, 2023RezzayoRezafungin · orphanMundipharma GmbHEMA ↗
Apr 25, 2008MycamineMicafunginSandoz Pharmaceuticals d.d.EMA ↗
Sep 20, 2007EcaltaAnidulafunginPfizer Europe MA EEIGEMA ↗
Oct 25, 2005NoxafilPosaconazoleMerck Sharp and Dohme B.VEMA ↗
Mar 19, 2002VfendVoriconazolePfizer Europe MA EEIGEMA ↗
Oct 23, 2001Cancidas (previously Caspofungin MSD)CaspofunginEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.